Aug. 12 at 4:42 PM
$ONCY – FDA Fast Track + Strong Early Data
Oncolytics Biotech just landed FDA Fast Track Designation for pelareorep in anal cancer — its second Fast Track indication alongside pancreatic cancer.
Why it matters:
✅ Data: GOBLET Cohort 1 (pancreatic) posted a 62% objective response rate and 45% one-year survival
✅ Data: REO 022 (colorectal) showed 27-month median OS vs. 11.2 months on standard treatment
✅ Partnerships: Roche, Pfizer, Merck Serono, Incyte, and Adlai Nortye all collaborating on combo studies
Likes to bottom out between .75-.80 level.
Patent protection now extends to 2044, and leadership just relocated HQ to San Diego with new COO and board additions. Next catalyst is the registration-focused study design in KRAS-mutant, MSS colorectal cancer. Investors are watching trial design details and regulatory next steps over coming quarters.
Communicated Disclaimer – https://stockresearchtoday.com/oncy/
NFA. DYOR.
$OFAL $RMCF $BIVI $DOGZ
